HDL Apomics:
HDL Apomics is looking at a new way to measure and develop pharmaceutical treatments in the cardiovascular theropeutic area by analyzing HDL.
- Technology Presenter: Scott Altmann
- Accelerator-Commercial Catalyst: Caroline Hoedemaker, VALUEDsolutions
- Defined Milestone: Prepare for fall Commercial Presentations to the Pharmaceutical Industry
- Targeted Completion: 1 months